Key result
Vildagliptin added to sulphonylurea monotherapy increased the odds of achieving an HbA1c reduction >0.3% without tolerability issues compared with other OADs (OR 1.6; 95% CI 1.36-1.86; p<0.0001).
Why the study?
Does vildagliptin improve the odds of achieving an HbA1c reduction of >0.3% without tolerability issues compared to other OADs in patients on first-line sulphonylurea therapy?
Observational
Yes
Does vildagliptin improve the odds of achieving an HbA1c reduction of >0.3% without tolerability issues compared to other OADs in patients on first-line sulphonylurea therapy?
Vildagliptin added to sulphonylurea monotherapy provides better glycaemic control without increased tolerability issues compared to other oral antidiabetic drugs in a real-world setting.
Answers are grounded in this paper and cite their sources.
May support vildagliptin addition to sulphonylurea in primary care; extends real-world observational data but remains hypothesis-generating.
AIM: In this post hoc analysis of the EDGE study, we assessed the effectiveness and safety of vildagliptin versus other oral antidiabetes drugs (OADs) as add-on to first-line sulphonylurea (SU) therapy in patients who did not receive metformin in a real-life setting. METHODS: The primary endpoint was odds of achieving an HbA1c reduction of >0.3% without tolerability issues. Secondary endpoint was odds of achieving HbA1c <7.0% without hypoglycaemia or weight gain. Changes in HbA1c, body weight; and safety were also assessed. The odds ratios for achieving primary and secondary endpoints were 1.6 (95% CI: 1.36, 1.86; p<0.0001) and 1.8 (1.45, 2.21; p<0.0001), respectively, in favour of vildagliptin. The between-treatment differences (vildagliptin vs. comparator OAD) for the mean change in HbA1c and body weight were -0.2±0.04% (p<0.0001) and -0.8±0.16kg (p<0.0001), respectively. Overall, the incidence of adverse events was low (vildagliptin, 7% vs. comparator, 8.2%) in both groups. Similar results were observed in a subset of patients enrolled from India and patients who received TZDs as a comparator OAD. CONCLUSION: Under real-life settings, vildagliptin as add-on to SU monotherapy showed better glycaemic response without tolerability issues compared with other OADs.
No takes yet. Share an insight, caveat, or question.
KUMAR et al. (2016) conducted an observational in Diabetes. Vildagliptin vs. Other oral antidiabetes drugs (OADs) was evaluated on Achieving an HbA1c reduction of >0.3% without tolerability issues (OR 1.6, 95% CI 1.36-1.86, p=<0.0001). Vildagliptin added to sulphonylurea monotherapy increased the odds of achieving an HbA1c reduction >0.3% without tolerability issues compared with other OADs (OR 1.6; 95% CI 1.36-1.86; p<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: